AC Immune Stock Receives 'Hold' Rating from Analysts

Biopharma firm's shares get mixed reviews from Wall Street

Mar. 13, 2026 at 6:51pm

Got story updates? Submit your updates here. ›

Shares of AC Immune (NASDAQ:ACIU) have been assigned an average rating of "Hold" from the five analysts currently covering the biopharmaceutical company, according to MarketBeat. One analyst has rated the stock with a "Sell" recommendation, one has given a "Hold" rating, and three have issued a "Buy" recommendation. The average 12-month target price among the analysts is $9.00.

Why it matters

AC Immune is a clinical-stage biopharma company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. The mixed analyst ratings reflect the challenges the company faces in advancing its pipeline and the competitive landscape in these therapeutic areas.

The details

The analysts' ratings on AC Immune's stock include one "Sell" recommendation, one "Hold" recommendation, and three "Buy" recommendations. Weiss Ratings reissued a "Sell (d-)" rating on the shares, while Jefferies Financial Group reiterated a "Buy" rating with a $7.00 target price. Wall Street Zen upgraded the stock from "Sell" to "Hold".

  • The analysts' ratings and target prices are based on their research and analysis over the last year.

The players

AC Immune

A clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in developing therapeutics and diagnostics for neurodegenerative diseases, with a focus on Alzheimer's and Parkinson's.

Weiss Ratings

A financial research and ratings firm that provides independent analysis and ratings on stocks, mutual funds, and other financial products.

Jefferies Financial Group

A global investment banking firm that provides research, sales and trading, and investment management services.

Wall Street Zen

A financial research and analysis firm that provides ratings and recommendations on stocks.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The mixed analyst ratings on AC Immune's stock reflect the challenges the company faces in advancing its pipeline of treatments for neurodegenerative diseases, which are highly competitive and complex therapeutic areas. Investors will be closely watching the company's progress in its clinical trials and regulatory approvals in the coming months and years.